TAIPEI CITY, Oct. 14, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Maxpro Capital Acquisition Corp. (NASDAQ: JMAC) (the “Company”) today announced that its sponsor, MP One Investment LLC (the “Sponsor”), has deposited an additional payment in the aggregate amount of $1,035,000 (representing 0.10 $ per public share) (the “Continuation Payment”) in the Company’s trust account for its public shareholders. This filing allows the Company to extend the date by which the Company must complete its first business combination from October 13, 2022 to January 13, 2023 (the “Extension”). The extension is the first of two three-month extensions permitted under the company’s incorporation documents. The extension gives the Company additional time to complete its first business combination with Apollomics Inc. (“Apollomics”), previously announced by the Company and Apollomics on September 14, 2022.
Sponsor has lent the Extension Payment to the Company, which loan is convertible, at Sponsor’s discretion, into units identical to the units issued under the Company’s private placement in the initial public offering. of the society.
About Maxpro Capital Acquisition Corp.
Maxpro is a blank check corporation formed for the purpose of effecting a merger, share capital exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more healthcare and technology companies. In October 2021, Maxpro completed a $103.5 million initial public offering of 10.35 million units (including the full exercise by the underwriters of their over-allotment option), each unit consisting of one Class A common share and one redeemable warrant, and each warrant entitling its holder to purchase one Class A common share at a price of $11.50 per share. On November 26, 2021, Maxpro announced that the holders of its units could elect to separately trade the Class A common shares and redeemable warrants included in the units. EF Hutton, a division of Benchmark Investments LLC, was the sole bookrunner for Maxpro’s IPO.
About Apollomics Inc.
Apollomics is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies that can be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics currently has a pipeline of nine drug candidates in multiple programs, six of which are currently in clinical development. Apollomics’ principal programs include the study of its lead product, vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with alterations in c-Met, which is currently in a Phase 2 multicohort clinical trial in the United States and development of an activating cancer drug candidate, uproleselan (APL-106), a specific E-selectin antagonist that has the potential to be used as an adjunct to standard chemotherapy to treat acute myeloid leukemia and other blood cancers, which is currently undergoing phase 1 and phase 3 clinical trials in China.
This press release may include, and oral statements made from time to time by representatives of the Company may include, “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1933. Exchange Act of 1934, as amended. Statements regarding possible business combinations and their financing, and related matters, and all other statements other than statements of historical facts included in this press release are forward-looking statements. When used in this press release, words such as “anticipate”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “could”, “plan”, “possible”, “potential”, “predict”, “project”, “should”, “would” and similar expressions, insofar as they relate to us or to our management team, identify forward-looking statements. These forward-looking statements are based on the beliefs of management, as well as assumptions made by the management of the Company and information currently available to them. Actual results could differ materially from those contemplated by the forward-looking statements due to certain factors detailed in the Company’s filings with the Securities and Exchange Commission (the “SEC”). All subsequent written or oral forward-looking statements attributable to us or persons acting on our behalf are qualified in their entirety by this paragraph. Forward-looking statements are subject to numerous conditions, many of which are beyond the Company’s control, including those set forth in the Risk Factors section of the Company’s registration statement and prospectus for the IPO of the Company filed with the SEC, Annual Report on Form 10-K for the fiscal year ended December 31, 2021, Company’s quarterly reports on Form 10-Q and other documents filed with the SEC. The Company assumes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Maxpro Capital Acquisition Corp.
Songren Road, Xinyi District
Attention: Moses Chen
Chief executive officer
+886 2 7713 7952